NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results

Executive stock purchases follow NEO100 Phase 2a data showing higher six-month progression-free survival than a 20% standard-of-care benchmark.

Rhea-AI Summary

NeOnc Technologies Holdings (NTHI)/b) reported that senior executives have purchased approximately $629,000 of company stock in open-market transactions since August 12, 2026, following positive NEO100 Phase 2a results.CEO Amir F. Heshmatpour bought an additional 35,000 shares on September 15, 2026 for about $115,400 at a weighted average price of $3.30 per share, bringing his total post-results purchases to 111,000 shares for roughly $418,700 at an average cost of $3.77 per share. Founder and Chief Medical Officer Thomas C. Chen acquired 49,016 shares for about $210,000, bringing combined executive purchases to 160,016 shares. The NEO100-01 Phase 2a trial met its primary endpoint, with six-month progression-free survival of 48.9% versus a 20% benchmark (p=0.0047) and median overall survival of 26.09 months. NeOnc also highlighted completion of Phase 1 dose escalation and a recommended Phase 2 dose for NEO212, and referenced a previously announced $15 million registered direct offering.

Positive

• Executives buy 160,016 shares in open market for approximately $629,000 since August 12, 2026
• CEO purchases 111,000 shares totaling about $418,700 at an average cost of $3.77 per share
• CEO personal investment exceeds $1.5 million in NeOnc shares over the past year, using personal funds
• NEO100 Phase 2a met primary endpoint with 48.9% six-month progression-free survival vs 20% benchmark (p=0.0047)
• Median overall survival in NEO100-01 Phase 2a was 26.09 months
• NEO212 program completed Phase 1 dose escalation and established a recommended Phase 2 dose
• $15 million registered direct offering was announced on September 9, 2026

Negative

• None.

News Explained

The disclosure adds completed insider buying, not a new issuance; the separate $15 million offering remains described as announced.

NeOnc reports completed open-market purchases by two executives using personal funds; the event described is separate from company financing and does not disclose a new share issuance by NeOnc.

A registered direct offering is a negotiated sale of registered securities to selected investors, whereas this release describes the executives' purchases as open-market transactions; the referenced $15 million offering is described here as announced, not closed.

The offering's gross amount equals 286.5 days of second-quarter operating cash use, while June 30, 2026 cash and equivalents equal 37.7 days at that rate; these are historical sizing comparisons, not a statement that the offering proceeds were already available as cash.

The release says the September 15, 2026 purchase will be reported in a Form 4.

Sources and calculations

• NeOnc executives open-market purchase release (2026-09-16)
• Registered direct offering definition (undated)
• NeOnc second-quarter fundamentals (2026Q2)

• Offering gross against the last reported quarterly operating outflow, in days at that rate $15,000,000 / ($4,765,181 / 91) = 286.5 days
• Available liquidity against the last reported quarterly operating outflow, in days at that rate $1,973,420 / ($4,765,181 / 91) = 37.7 days

Argus 15 min delay

-6.95% vs previous close $3.08 last price 2.1x rel. volume Open Argus

Details

Market reaction after insider stock purchases: NTHI -6.95%

$3.06 $3.55 Day Range

$88.72M Market Cap

Following this news, NTHI has declined 6.95%, reflecting a notable negative market reaction. Our momentum scanner has triggered 14 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $3.08. Trading volume is elevated at 2.1x the average, suggesting increased selling activity.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The stock was down 12.43% before publication, while the announcement disclosed executive open-market...

Analysis

The stock was down 12.43% before publication, while the announcement disclosed executive open-market buying; that move preceded the news and therefore does not measure a reaction to these purchases.

Key Figures

Combined executive purchases: 160,016 shares Combined purchase value: $629,000 Latest CEO purchase: 35,000 shares +5 more

Combined executive purchases

160,016 shares

Open-market purchases by two executives

Combined purchase value

$629,000

Open-market purchases by two executives

Latest CEO purchase

35,000 shares

September 15, 2026 open-market purchase

Latest CEO purchase value

$115,400

September 15, 2026 open-market purchase

CEO cumulative purchases

111,000 shares

Since the August 12, 2026 NEO100 Phase 2a results announcement

Six-month progression-free survival

48.9%

NEO100-01 Phase 2a study

P-value

p=0.0047

NEO100-01 Phase 2a primary endpoint

Median overall survival

26.09 months

NEO100-01 Phase 2a study

Historical Context

2 past events · Latest: Sep 15

2 events

1. Sep 15

   Insider share purchase

   24h Move

   -12.4%

   CEO purchased additional shares after the company announced a $15 million financing

2. Sep 14

   Insider share purchase

   24h Move

   +2.7%

   CEO purchased shares as NEO100 advanced toward a regulatory discussion

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 4, phase 2a, progression-free survival, overall survival, +1 more

5 terms

form 4 regulatory

"as reflected in Form 4 filings with the SEC"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

View in glossary

phase 2a medical

"positive NEO100 Phase 2a results"

Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.

progression-free survival medical

"six-month progression-free survival of 48.9%"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

overall survival medical

"median overall survival of 26.09 months"

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

fda fast-track regulatory

"advancing under FDA Fast-Track and Investigational New Drug"

A U.S. Food and Drug Administration (FDA) fast-track designation is a regulatory program that speeds the development and review of a drug or biologic intended to treat a serious condition when there is an unmet medical need. It gives the sponsor more frequent interactions with the agency and options like rolling review of application materials, which can shorten the route to approval. For investors, fast-track status can reduce regulatory uncertainty and potentially accelerate the timeline for a product to reach market, similar to getting access to an express lane in a regulatory review process.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CEO Amir Heshmatpour has purchased 111,000 shares for approximately $418,700 since the Company announced positive NEO100 Phase 2a results

CALABASAS, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Executive Chairman, President and Chief Executive Officer Amir F. Heshmatpour purchased an additional 35,000 shares of NeOnc common stock in the open market on September 15, 2026, for approximately $115,400, at a weighted average price of approximately $3.30 per share, as will be reported in a Form 4 filed with the U.S. Securities and Exchange Commission (SEC).

The purchase follows the Company's $15 million registered direct offering announced on September 9, 2026, and extends a series of open-market purchases by NeOnc's senior leadership since the Company reported positive topline Phase 2a results for intranasal NEO100™ on August 12, 2026. Since that announcement, Mr. Heshmatpour has purchased 111,000 shares for a total of approximately $418,700, at an average cost of approximately $3.77 per share. Thomas C. Chen, MD, PhD, Founder, Chief Medical Officer and Chief Scientific Officer, has purchased 49,016 shares for approximately $210,000. Together, the two executives have purchased 160,016 shares for approximately $629,000 in the open market, as reflected in Form 4 filings with the SEC, including the Form 4 to be filed for the September 15 purchases.

“The strength of our Phase 2a results reinforces my conviction in NeOnc's mission and the potential of our NEO platform,” said Mr. Heshmatpour. “With my most recent open-market purchases, I have now invested more than $1.5 million of my personal funds in NeOnc shares over the past year. This is a personal investment in our mission, our patients and the long-term value we are working to build alongside our shareholders.”

The NEO100-01 Phase 2a study met its primary endpoint, with six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047), and median overall survival of 26.09 months. The Company’s second clinical program, NEO212, has completed Phase 1 dose escalation and established a recommended Phase 2 dose.

All purchases were made in the open market using personal funds.

About NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.

For more about NeOnc and its pioneering technology, visit https://neonc.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential of NEO100, the interpretation and significance of the Phase 2a results, plans to engage with the FDA, the design and timing of future clinical trials, and the Company's development strategy. These statements are based on management's current expectations and are subject to known and unknown risks and uncertainties that may cause actual results to differ materially.

Such risks include, but are not limited to: the Phase 2a study was a single-arm, open-label study of 24 patients that did not reach its planned enrollment of 28 patients and was not powered as a confirmatory trial; results were not compared against a randomized control arm, and comparisons to historical data are inherently limited by differences in patient population, era, and assessment criteria; the primary efficacy analysis presented reflects RANO 2.0 criteria and Kaplan-Meier estimation, and results differ under the response criteria and estimation method specified in the study protocol; early-phase results frequently fail to replicate in larger, controlled studies; safety and tolerability findings in a 24-patient, open-label study may not predict the safety profile observed in larger or longer-duration studies, and additional adverse events may emerge with broader exposure; the FDA may not agree with the Company's proposed registrational path, endpoints, or analytical methods; and additional pre-specified analyses remain ongoing. Additional risks are described in the Company's filings with the U.S. Securities and Exchange Commission.

The Company undertakes no obligation to update any forward-looking statement except as required by law.

“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Contacts

Company Contact:
info@neonc.com

Investor Contact:
Jon Nugent
Jon Nugent Communications
jon@jonnugent.com
205-566-3026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NeOnc shares did Amir F. Heshmatpour recently purchase and at what price?

On September 15, 2026, Executive Chairman, President and CEO Amir F. Heshmatpour purchased an additional 35,000 shares of NeOnc common stock in the open market for approximately $115,400, at a weighted average price of about $3.30 per share. Since the August 12, 2026 announcement of positive NEO100 Phase 2a topline results, he has bought a total of 111,000 shares for roughly $418,700, at an average cost of about $3.77 per share, using personal funds.

What are the key efficacy results from the NEO100-01 Phase 2a study?

The NEO100-01 Phase 2a study of intranasal NEO100 met its primary endpoint. Six-month progression-free survival was 48.9%, compared with a pre-specified 20% benchmark for standard of care, with a reported p-value of 0.0047. Median overall survival in the study was 26.09 months.

What progress has NeOnc reported for its second clinical program, NEO212?

For NEO212, NeOnc reported that the program has completed Phase 1 dose escalation and has established a recommended Phase 2 dose, positioning the therapy for further Phase 2 development.

How were the executive share purchases funded and how are they reported?

NeOnc stated that all purchases were made in the open market using personal funds. The transactions are reflected in Form 4 filings with the U.S. Securities and Exchange Commission, including the Form 4 to be filed for the September 15, 2026 purchases.